Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Sodium Cromoglicate
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Respivant Sciences Supports International Rare Disease Day Through Awareness Activities
Details : Respivant also announces 50% enrollment milestone achieved in SCENIC, a Phase 2b Trial of RVT-1601 for the Treatment of Idiopathic Pulmonary Fibrosis (IPF).
Brand Name : Undisclosed
Molecule Type : Small molecule
Upfront Cash : Not Applicable
February 28, 2020
Lead Product(s) : Sodium Cromoglicate
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase II
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?